NO20083492L - 11-Beta HSD1 inhibitorer - Google Patents
11-Beta HSD1 inhibitorerInfo
- Publication number
- NO20083492L NO20083492L NO20083492A NO20083492A NO20083492L NO 20083492 L NO20083492 L NO 20083492L NO 20083492 A NO20083492 A NO 20083492A NO 20083492 A NO20083492 A NO 20083492A NO 20083492 L NO20083492 L NO 20083492L
- Authority
- NO
- Norway
- Prior art keywords
- hsd1 inhibitors
- beta hsd1
- beta
- inhibitors
- hsd1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Foreliggende oppfinnelse angår hemmende 11-?-HSD1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77126206P | 2006-02-07 | 2006-02-07 | |
PCT/US2007/003134 WO2007092435A2 (en) | 2006-02-07 | 2007-02-07 | 11-beta hsd1 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20083492L true NO20083492L (no) | 2008-10-28 |
Family
ID=38236242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20083492A NO20083492L (no) | 2006-02-07 | 2008-08-12 | 11-Beta HSD1 inhibitorer |
Country Status (18)
Country | Link |
---|---|
US (2) | US7632838B2 (no) |
EP (1) | EP1981848A2 (no) |
JP (1) | JP2009526059A (no) |
KR (1) | KR20080093072A (no) |
CN (1) | CN101400653A (no) |
AR (1) | AR059355A1 (no) |
AU (1) | AU2007212429A1 (no) |
BR (1) | BRPI0707537A2 (no) |
CA (1) | CA2641609A1 (no) |
CR (1) | CR10186A (no) |
GT (1) | GT200800151A (no) |
IL (1) | IL193157A0 (no) |
NO (1) | NO20083492L (no) |
PA (1) | PA8713501A1 (no) |
PE (1) | PE20071232A1 (no) |
RU (1) | RU2008132333A (no) |
TW (1) | TW200800898A (no) |
WO (1) | WO2007092435A2 (no) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007111921A1 (en) * | 2006-03-23 | 2007-10-04 | Amgen Inc. | 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxsteroid dehydrogenases |
WO2007135427A1 (en) * | 2006-05-23 | 2007-11-29 | Astrazeneca Ab | 1,4-disubstituted piperazine and 1,4-disubstituted azepane as 11 -beta-hydroxysteroid dehydrogenase 1 inhibitors |
PE20080932A1 (es) * | 2006-11-10 | 2008-07-13 | Wyeth Corp | Piperidinil 4-arilsulfonamidas n-sustituidas como moduladores de la proteina 1 secretada relacionada con frizzled (sfrp-1) |
JP2010518109A (ja) * | 2007-02-07 | 2010-05-27 | ワイス エルエルシー | ハロゲン化アミンの製造法 |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
CA2697551C (en) | 2007-09-20 | 2013-03-12 | Irm Llc | Piperidine derivatives as modulators of gpr119 activity |
WO2009051244A1 (ja) * | 2007-10-18 | 2009-04-23 | Takeda Pharmaceutical Company Limited | 複素環化合物 |
CN101597278B (zh) | 2008-06-04 | 2013-04-17 | 中国中化股份有限公司 | 酰胺类化合物及其制备与应用 |
GB0818241D0 (en) * | 2008-10-06 | 2008-11-12 | Cancer Res Technology | Compounds and their use |
AR074318A1 (es) | 2008-11-14 | 2011-01-05 | Nycomed Gmbh | Derivados heterociclicos de pirazolona, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades de las vias respiratorias. |
WO2010141550A2 (en) * | 2009-06-04 | 2010-12-09 | Wyeth Llc | 11-beta hsd1 inhibitors |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
CN103096893B (zh) | 2010-06-04 | 2016-05-04 | 阿尔巴尼分子研究公司 | 甘氨酸转运体-1抑制剂、其制备方法及其用途 |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2013004642A1 (en) * | 2011-07-01 | 2013-01-10 | Remynd Nv | 1, 2, 4 -thiadiazol- 5 -ylpiperazine derivatives useful in the treatment neurodegenerative diseases |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US10092574B2 (en) | 2012-09-26 | 2018-10-09 | Valorisation-Recherche, Limited Partnership | Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof |
JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
JP6339416B2 (ja) * | 2014-05-28 | 2018-06-06 | 国立大学法人 名古屋工業大学 | 光学活性スルホンアミド誘導体の製造方法 |
CN104974084A (zh) * | 2015-07-19 | 2015-10-14 | 佛山市赛维斯医药科技有限公司 | 一类胺基二吡啶叔醇结构的11β-HSD1抑制剂及其用途 |
EP3235813A1 (en) | 2016-04-19 | 2017-10-25 | Cidqo 2012, S.L. | Aza-tetra-cyclo derivatives |
WO2018140513A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
US11136308B2 (en) | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
WO2018140599A1 (en) * | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
US11274093B2 (en) | 2017-01-26 | 2022-03-15 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
WO2018218069A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant kras, hras or nras |
US10745385B2 (en) | 2017-05-25 | 2020-08-18 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
GB201713780D0 (en) * | 2017-08-29 | 2017-10-11 | E-Therapeutics Plc | Modulators of hedgehog (Hh) signalling pathway |
AU2019339777B2 (en) | 2018-09-12 | 2022-09-01 | Novartis Ag | Antiviral pyridopyrazinedione compounds |
WO2020117972A1 (en) * | 2018-12-04 | 2020-06-11 | The Board Of Regents Of The University Of Texas System | Therapeutics targeting mutant adenomatous polyposis coli (apc) for the treatment of cancer |
CN111943893A (zh) * | 2019-05-17 | 2020-11-17 | 南京爱德程医药科技有限公司 | 4,7-二氮杂螺[2.5]辛烷类化合物的合成方法 |
HUE062445T2 (hu) * | 2019-07-22 | 2023-11-28 | Evonik Operations Gmbh | Anionvezetõ polimer membrán |
CA3155287A1 (en) | 2019-09-26 | 2021-04-01 | Novartis Ag | Antiviral pyrazolopyridinone compounds |
JP2023508955A (ja) * | 2019-12-24 | 2023-03-06 | ザイダス・ライフサイエンシーズ・リミテッド | 脂質異常症の治療に適した新規な化合物 |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2875205A (en) * | 1959-02-24 | Chj-chj | ||
ZA813332B (en) * | 1980-06-21 | 1982-05-26 | Pfizer | Larvicides and isecticides |
JPS6081168A (ja) * | 1983-10-13 | 1985-05-09 | Asahi Chem Ind Co Ltd | アミジン誘導体 |
FR2553414B1 (fr) | 1983-10-18 | 1986-08-14 | Choay Sa | Nouveaux benzenesulfonamides n-cyclises, leur procede de preparation et leur utilisation comme substance active de compositions pharmaceutiques |
US4857644A (en) * | 1988-06-09 | 1989-08-15 | American Home Products Corporation | Aryl sulfonopiperazines as anti-inflammatory agents |
WO1993012086A1 (en) * | 1991-12-11 | 1993-06-24 | Ss Pharmaceutical Co., Ltd. | Arylamide derivative |
EP0661266A1 (en) | 1993-12-27 | 1995-07-05 | Toa Eiyo Ltd. | Substituted cyclic amine compounds as 5HT2 antagonists |
US5464788A (en) | 1994-03-24 | 1995-11-07 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
WO1997036876A1 (en) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6063930A (en) * | 1996-04-03 | 2000-05-16 | Merck & Co., Inc. | Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors |
JP2000513711A (ja) | 1996-04-18 | 2000-10-17 | メルク エンド カンパニー インコーポレーテッド | 癌の治療法 |
WO1997045412A1 (en) | 1996-05-30 | 1997-12-04 | Merck & Co., Inc. | A method of treating cancer |
WO1998044797A1 (en) | 1997-04-07 | 1998-10-15 | Merck & Co., Inc. | A method of treating cancer |
US6297239B1 (en) * | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
US6673799B1 (en) | 1998-09-22 | 2004-01-06 | Yamanouchi Pharmaceutical Co. Ltd. | Cyanophenyl derivative |
WO2000025789A1 (en) | 1998-10-29 | 2000-05-11 | Merck & Co., Inc. | A method of treating endometriosis |
WO2000056704A1 (en) * | 1999-03-22 | 2000-09-28 | Darwin Discovery Limited | Hydroxamic and carboxylic acid derivatives |
WO2001066534A2 (en) | 2000-03-09 | 2001-09-13 | Abbott Laboratories | Cyclic and bicyclic diamino histamine-3 receptor antagonists |
JP2001261657A (ja) | 2000-03-17 | 2001-09-26 | Yamanouchi Pharmaceut Co Ltd | シアノフェニル誘導体 |
JP2001328938A (ja) | 2000-03-17 | 2001-11-27 | Yamanouchi Pharmaceut Co Ltd | シアノフェニル誘導体を有効成分とする医薬 |
WO2001098878A2 (de) * | 2000-06-16 | 2001-12-27 | Baumüller Anlagen-Systemtechnik GmbH & Co. | Verfahren zum automatischen erzeugen mehrerer elektrischer impulse anhand numerischer vorgabewerte, insbesondere als inkrementalgeber-nachbildung |
AU2001288432A1 (en) * | 2000-09-01 | 2002-03-22 | Icos Corporation | Materials and methods to potentiate cancer treatment |
EP1217000A1 (en) * | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
GB0108591D0 (en) * | 2001-04-05 | 2001-05-23 | Merck Sharp & Dohme | Therapeutic agents |
GB0120347D0 (en) * | 2001-08-21 | 2001-10-17 | Merck Sharp & Dohme | Therapeutic agents |
MXPA04001607A (es) | 2001-08-21 | 2004-07-08 | Merck Sharp & Dohme | Ciclohexilsulfonas novedosas. |
MXPA04004837A (es) | 2001-11-22 | 2004-08-02 | Biovitrum Ab | Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1. |
AU2002353717B2 (en) | 2001-11-22 | 2006-08-03 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
OA12792A (en) | 2002-03-13 | 2006-07-10 | Janssen Pharmaceutica Nv | Sulfonyl-derivatives as novel inhibitors of histone deacetylase. |
JP2005533858A (ja) | 2002-07-27 | 2005-11-10 | アストラゼネカ アクチボラグ | 化合物 |
AU2003269242A1 (en) | 2002-10-11 | 2004-05-04 | Astrazeneca Ab | 1,4-disubstituted piperidine derivatives and their use as 11-betahsd1 inhibitors |
US20060058315A1 (en) | 2002-11-07 | 2006-03-16 | Astrazeneca Ab | 2-Oxo-ethanesulfonamide derivates |
TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
US20060258683A1 (en) | 2003-04-07 | 2006-11-16 | Liu Kevin | Para-sulfonyl substituted phenyl compounds as modulators of ppars |
EP1615697A2 (en) | 2003-04-11 | 2006-01-18 | Novo Nordisk A/S | New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof |
WO2004089416A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent |
AU2004261250B2 (en) | 2003-07-29 | 2009-02-26 | Xenon Pharmaceuticals Inc. | Pyridyl derivatives and their use as therapeutic agents |
ATE532772T1 (de) | 2003-07-30 | 2011-11-15 | Xenon Pharmaceuticals Inc | Piperazinderivate und deren verwendung als therapeutische mittel |
WO2005011656A2 (en) | 2003-07-30 | 2005-02-10 | Xenon Pharmaceuticals Inc. | Pyridyl derivatives and their use as therapeutic agents |
US20050124625A1 (en) * | 2003-10-21 | 2005-06-09 | Salvati Mark E. | Piperazine derivatives and their use as modulators of nuclear hormone receptor function |
GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
WO2005063247A1 (en) | 2003-12-22 | 2005-07-14 | Amgen Inc. | Aryl sulfonamide compounds and uses related thereto |
JP2007519726A (ja) | 2004-01-26 | 2007-07-19 | メルク エンド カムパニー インコーポレーテッド | 11−ベータ−ヒドロキシステロイドデヒドロゲナーゼ1型の阻害剤の、新規結晶形態 |
WO2005089502A2 (en) | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
AR048523A1 (es) * | 2004-04-07 | 2006-05-03 | Kalypsys Inc | Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos |
ES2350113T3 (es) | 2004-04-14 | 2011-01-18 | Amgen Inc. | Arilsulfonas y usos relacionados con las mismas. |
MXPA06012143A (es) | 2004-04-20 | 2007-05-15 | Amgen Inc | Arilsulfonamidas y usos relacionados con las mismas. |
TWI350168B (en) | 2004-05-07 | 2011-10-11 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
CA2567343A1 (en) | 2004-05-20 | 2005-12-01 | Elan Pharmaceuticals, Inc. | N-cyclic sulfonamido inhibitors of gamma secretase |
US7687665B2 (en) | 2004-06-24 | 2010-03-30 | Incyte Corporation | 2-methylprop anamides and their use as pharmaceuticals |
US20060009491A1 (en) | 2004-06-24 | 2006-01-12 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
US20060009471A1 (en) | 2004-06-24 | 2006-01-12 | Wenqing Yao | Amido compounds and their use as pharmaceuticals |
AU2005256442B2 (en) * | 2004-06-28 | 2009-02-12 | F. Hoffmann-La Roche Ag | Pyrimidine derivatives as 11beta-HSD1 inhibitors |
ATE461926T1 (de) | 2004-06-30 | 2010-04-15 | Schering Corp | Substituierte n-arylsulfonylheterocyclische amine als gamma-sekretase-hemmer |
KR100926842B1 (ko) * | 2004-07-28 | 2009-11-13 | 에프. 호프만-라 로슈 아게 | 11-베타-hsd1 억제제로서의 아릴-피리딘 유도체 |
US20060025445A1 (en) * | 2004-08-02 | 2006-02-02 | Xiang Jason S | 11-Beta HSD1 inhibitors |
EP1809620B1 (en) | 2004-11-04 | 2010-12-29 | Addex Pharma SA | Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
GB0510143D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
EP1866298A2 (en) | 2005-03-31 | 2007-12-19 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
WO2007055942A2 (en) * | 2005-11-03 | 2007-05-18 | Merck & Co., Inc. | Substituted nicotinamide compounds |
WO2007070506A2 (en) * | 2005-12-14 | 2007-06-21 | Amgen Inc. | Diaza heterocyclic sulfonamide derivatives and their uses |
CA2634250A1 (en) * | 2005-12-21 | 2007-07-05 | Schering Corporation | Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists |
-
2007
- 2007-02-07 JP JP2008554299A patent/JP2009526059A/ja not_active Withdrawn
- 2007-02-07 RU RU2008132333/04A patent/RU2008132333A/ru not_active Application Discontinuation
- 2007-02-07 CN CNA2007800088400A patent/CN101400653A/zh active Pending
- 2007-02-07 AU AU2007212429A patent/AU2007212429A1/en not_active Abandoned
- 2007-02-07 WO PCT/US2007/003134 patent/WO2007092435A2/en active Application Filing
- 2007-02-07 EP EP07717205A patent/EP1981848A2/en not_active Withdrawn
- 2007-02-07 AR ARP070100510A patent/AR059355A1/es unknown
- 2007-02-07 PA PA20078713501A patent/PA8713501A1/es unknown
- 2007-02-07 PE PE2007000130A patent/PE20071232A1/es not_active Application Discontinuation
- 2007-02-07 BR BRPI0707537-5A patent/BRPI0707537A2/pt not_active IP Right Cessation
- 2007-02-07 KR KR1020087021870A patent/KR20080093072A/ko not_active Application Discontinuation
- 2007-02-07 TW TW096104455A patent/TW200800898A/zh unknown
- 2007-02-07 US US11/703,522 patent/US7632838B2/en not_active Expired - Fee Related
- 2007-02-07 CA CA002641609A patent/CA2641609A1/en not_active Abandoned
-
2008
- 2008-07-30 CR CR10186A patent/CR10186A/es not_active Application Discontinuation
- 2008-07-31 IL IL193157A patent/IL193157A0/en unknown
- 2008-08-07 GT GT200800151A patent/GT200800151A/es unknown
- 2008-08-12 NO NO20083492A patent/NO20083492L/no not_active Application Discontinuation
-
2009
- 2009-08-11 US US12/539,232 patent/US20100029648A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
RU2008132333A (ru) | 2010-03-20 |
EP1981848A2 (en) | 2008-10-22 |
JP2009526059A (ja) | 2009-07-16 |
AU2007212429A1 (en) | 2007-08-16 |
KR20080093072A (ko) | 2008-10-17 |
US20100029648A1 (en) | 2010-02-04 |
AR059355A1 (es) | 2008-03-26 |
US20070219198A1 (en) | 2007-09-20 |
CR10186A (es) | 2008-10-29 |
IL193157A0 (en) | 2009-02-11 |
GT200800151A (es) | 2008-11-03 |
WO2007092435A3 (en) | 2007-12-27 |
CA2641609A1 (en) | 2007-08-16 |
PE20071232A1 (es) | 2008-02-18 |
WO2007092435A2 (en) | 2007-08-16 |
PA8713501A1 (es) | 2009-09-17 |
TW200800898A (en) | 2008-01-01 |
US7632838B2 (en) | 2009-12-15 |
BRPI0707537A2 (pt) | 2011-05-03 |
CN101400653A (zh) | 2009-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20083492L (no) | 11-Beta HSD1 inhibitorer | |
LTPA2017010I1 (lt) | Proteazomos inhibitoriai | |
CL2007002182S1 (es) | Terminal. | |
SMP200900058B (it) | Composti e composizioni come inibitori di proteinachinasi. | |
SM201000108A (it) | Composti e composizioni come inibitori di proteinachinasi. | |
EA201001359A1 (ru) | Гетероциклические соединения в качестве ингибиторов cxcr2 | |
ATE490254T1 (de) | Imidazoä1,2-aüpyridin-verbindungen als vegf-r2- hemmer | |
DE602007012072D1 (de) | Orantagonisten | |
DK2383271T3 (da) | Aminoquinoloner som GSK-3-inhibitorer | |
PL2126020T3 (pl) | Hydrofobowo modyfikowane polialkilenoiminy jako inhibitory przenoszenia barwnika | |
BRPI0815715A2 (pt) | compostos 5-(-4-(haloalcóxi)fenil)pirimidina-2-amina e composições como inibidores de quinases. | |
BRPI1015043A2 (pt) | derivados de diazahomoadamantano e métodos de uso dos mesmos | |
DE502006005053D1 (de) | Spritzbare akustikmassen | |
UY31688A1 (es) | Plaguicidas | |
BRPI0813867A2 (pt) | Composições compreendendo inibidores e hidrolase de triptofano. | |
ZA200801444B (en) | Pyrazolone derivatives as 11-Beta HSD1 inhibitors | |
CO6241120A2 (es) | (DIHIDRO)PIRROLO[2,1-á]ISOQUINOLINAS. | |
BRPI0814772A2 (pt) | Indazóis substituídos por 5-piridinona | |
UA107689C2 (en) | 3,4,4A,10B-TETRAHYDRO-1H-THIOPYRANO-[4, 3-c] ISOQUINOLINE DERIVATIVES | |
ATE430148T1 (de) | Neue pyrrolodihydroisochinoline als pde10- inhibitoren | |
ATE418545T1 (de) | Nnrt-inhibitoren | |
EA201170585A1 (ru) | Производные изохинолинона в качестве антагонистов nk3 | |
ATE461189T1 (de) | Neue 6-pyridylphenanthridine | |
NO20091386L (no) | Fenyloksyanilinderivater | |
RS53014B (en) | 4R, 5S-ENANTIOMER 2- (5-METHYL-2-OXO-4-PHENYL-PYROLIDIN-1-IL) -ACETAMIDE WITH NOOTROPIC ACTIVITY |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |